Home
overview

World-wide sales of vaccines in 1998 exceeded $4 billion and are expected to exceed approximately $10 billion by 2005. Recombinant DNA technology has enabled the development of prophylactic vaccine products that are safer, cheaper and easier to manufacture.

This conference will assess the following key issues

Vaccine industry in the 21st Century

Global demand for vaccines

Prevalence of Ad35 in the healthy human population

The role of vaccines in addressing the resistance threat

Immunological mechanisms, delivery systems and clinical implications

Delivering the DNA-gold complex directly into the target tissue

Offering improved safety and efficacy over needle based delivery methods

Vaccines development for combating bio-terrorism

Compliance with regulatory requirements and customer expectations

Confirmed Speakers include Dr Stephen Lockhart, Senior Director, European Vaccine Clinical Research, Wyeth Vaccines

Dr Clive Dix, Senior Vice President, Research & Development, PowderJect

Dr Keith Williams, Head, Vaccines, AstraZeneca

Dr Carlo Russo, Director, Regulatory Liaison, Merck

Dr David Page, Senior Scientist, Elan

Dr Kathrin Jansen, Senior Director, Microbial Vaccine Research, Merck

Dr Una Ryan, President & Chief Executive Officer, Avant

Dr Thomas Dubensky, Vice President, Vaccines, Cerus

Prof. Jaap Goudsmit, Executive Vice President, Vaccine Research & Chief Medical Officer, Crucell

Dr John Connolly, Gene Therapy Advisory Committee, Department of Health

Dr Jenny Best, Reader, Virology, Kings College London

Past comments from Previous SMi Pharmaceutical conference delegates

Wonderful meeting overall! Speakers of a very high calibre. SMi staff is top notch. Thanks for everything.

Christopher Marlor, Manager, Exploratory Biology, Achillion

"A good solid conference professionally put together"

Mark Robbins, Chief Executive, Uquifa

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Jenny Best

Dr Jenny Best, Reader, Virology, Kings College London

9:10 THE VACCINE INDUSTRY IN THE 21ST CENTURY

Michel Greco

Michel Greco, Deputy Chief Executive Officer, Aventis Pasteur

  • A special market
  • Strong growth drivers
  • A concentrated industry
  • Facing major issues and challenges
  • What is ahead for the industry?
  • 9:40 INFECTION STRATEGY

    Keith Williams

    Keith Williams, Global Product Director, Infection Therapy Area Management Team (TAMT), AstraZeneca

  • The changing epidemiology of infection
  • Infections not well treated at present
  • Current and future resistance problems
  • Changing demography and changing medical practice
  • 10:20 REGULATORY ISSUES FOR NEW VACCINE TECHNOLOGIES

    Dr Carlo Russo

    Dr Carlo Russo, Executive Director, Global Strategic Regulatory Development, Vaccines/Biologics, Merck

  • Review of emerging safety considerations
  • New delivery methods and the safety issues surrounding them
  • Risk communication
  • Principles of risk communications
  • Lessons from recent controversies in vaccine safety
  • Thinking strategically about vaccine safety
  • 11:00 Morning Coffee

    11:20 TICK-BORNE ENCEPHALITIS

    Dr Michael Broeker

    Dr Michael Broeker, Clinical Research & Medical Affairs, Chiron

  • Clinical picture
  • Epidemiology of the virus
  • Prevention by vaccines
  • 12:00 GENETIC VACCINATION STRATEGIES

    Dr John Connolly

    Dr John Connolly, Secretary, Gene Therapy Advisory Committee, Department of Health

  • Genetic immunotherapy
  • DNA vaccine applications
  • Vaccines based on viral vectors
  • Cancer vaccines
  • Strategies for control of infectious diseases, including HIV
  • Ethics considerations
  • 12:40 Lunch

    14:00 TECHNOLOGICAL OPPORTUNITIES AND ECONOMIC INCENTIVES TO VACCINE DEVELOPMENT

    Dr Rino Rappuoli

    Dr Rino Rappuoli, Head, Research, Chiron

  • The present era is one of the best moments in history for vaccine development
  • The information provided by the genomic era has enabled all possible antigens of nearly all pathogenic microorganisms to be extracted from databases
  • The progress in immunology and vaccine delivery is making it possible to target all arms of the immune system
  • GAVI and the vaccine fund are making an unprecedented amount of money available
  • Nevertheless, vaccines are not a priority for industry and this may jeopardise the future of vaccines unless properly addressed on a global basis
  • 14:40 DEVELOPING DNA VACCINES

    Dr David Page

    Dr David Page, Senior Scientist, Elan

  • Modulation of immune responses and antigen processing
  • Viral or non-viral vectors?
  • Targeting dendritic cells
  • Improved DNA vaccines
  • Clinical implications
  • Non delivery approaches
  • 15:20 Afternoon Tea

    15:40 ADMINISTRATION OF DNA AND CONVENTIONAL VACCINES

    Dr Clive Dix

    Dr Clive Dix, Senior Vice President, Research & Development, PowderJect

  • Developing a novel formulation of DNA
  • Adhering DNA to microscopic gold particles
  • Delivering the DNA-gold complex directly into the target tissue
  • Offering improved safety and efficacy over needle based delivery methods
  • Pharmacoeconomical aspects of their DNA vaccine technology
  • Benefits for the patient
  • 16:20 STATUS OF PROPHYLACTIC VACCINES AGAINST CERVICAL CANCER

    Dr Kathrin Jansen

    Dr Kathrin Jansen, Senior Director, Microbial Vaccine Research, Merck

  • Prophylactic HPV vaccine
  • Clinical trials
  • Immunogenicity
  • Efficacy
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Philip Minor

    Dr Philip Minor, Head, Division, Virology, National Institute of Biological Standards and Control

    9:10 DEVELOPMENT OF VACCINES AGAINST SELF ANTIGENS: THE P53 PARADIGM

    Dr Sunil Chada

    Dr Sunil Chada, Director, Research & Development, Introgen Therapeutics

  • Tumor antigens – pros and cons
  • Delivery strategies
  • Augmenting antigen presentation
  • Validation models
  • Clinical safety studies
  • 9:40 IMMUDAPTIN: HARNESSING INNATE IMMUNITY

    Dr Richard Smith

    Dr Richard Smith, Chief Scientific Officer, AdproTech

  • C3d: a natural immunopotentiator
  • Tandem arrays of C3d in a recombinant vaccine
  • Enhancement of titre, avidity and speed of response
  • DNA vaccines for influenza, HIV and measles containing C3d
  • Protein and DNA vaccines for malaria containing C3d
  • 10:20 CONJUGATED VACCINES

    Dr Stephen Lockhart

    Dr Stephen Lockhart, Senior Director, Head, Bacterial Vaccine Clinical Research, Wyeth Vaccine Research

  • What are conjugated vaccines?
  • Different types of conjugated vaccines
  • Successes so far
  • Potential new areas for conjugated vaccines
  • Challenges faced in the development of conjugated vaccines
  • 11:00 Morning Coffee

    11:20 A NOVEL VACCINE APPROACH TO CHOLESTEROL MANAGEMENT

    Dr Una Ryan

    Dr Una Ryan, President & Chief Executive Officer, AVANT Immunotherapeutics

  • HDL is an important negative risk factor for atherosclerosis
  • CETP regulates HDL levels
  • Vaccine approaches can inhibit CETP
  • Inhibiting CETP raises HDL and reduces lesions in rabbits
  • AVANT’s vaccine has been in phase II clinical trials since August 2001
  • AVANT’s vaccine, CETi-1, should raise HDL, improve compliance and lower costs
  • 12:00 ANTIBODIES TO ACTIVATE, INACTIVATE OR SWITCH IMMUNE RESPONSES

    Dr Birgit Schultes

    Dr Birgit Schultes, Vice President, Research, AltaRex

  • Novel methods utilise monoclonal antibodies to alter immune responses
  • Phase II clinical trials results for ovarian cancer
  • Antibodies in preclinical testing: targeting CA125, MUC1, PSA CA19.9 and TAG-72
  • Applicability of technology in infectious diseases, allergies, and autoimmune diseases
  • 12:40 Lunch

    14:00 POXVIRUSES AS VECTORS FOR CANCER IMMUNOTHERAPY

    Dr Miles Carroll

    Dr Miles Carroll, Vice President, Oxford BioMedica

  • Advantages of poxviruses as vaccine vectors
  • 5T4: a novel tumour associated antigen
  • TroVax: attenuated poxvirus, MVA, expressing 5T4
  • Evaluation of Trovax in phase I/II clinical trials in late stage colorectal cancer patients
  • 14:40 AD35 VECTORS

    Prof Jaap Goudsmit

    Prof Jaap Goudsmit, Executive Vice President, Vaccine Research & Chief Medical Officer, Crucell

  • Prevalence of Ad35 in the healthy human population
  • Prevalence of Ad35 in immuno compromised patients
  • Vector systems, packaging cells and vector production yields
  • Antigen presenting cell tropism of Ad35
  • Potency of recombinant Ad35 to induce immunity in rodents and non-human primates
  • 15:20 Afternoon Tea

    15:40 CHALLENGES FACED WITH POTENCY

    Dr Thomas Dubensky

    Dr Thomas Dubensky, Vice President, Cancer Vaccines Research, Cerus

  • Review of vector platforms for therapeutic vaccines
  • Vaccine approaches for incorporating innate and adaptive arms of the immune response
  • Cancer vaccine strategies
  • Encouraging results in early phase cancer vaccine human clinical trials
  • Manufacturing considerations
  • Safety considerations
  • 16:20 MANUFACTURING STRATEGIES IN A GROWING MARKET SECTOR

    Dr Amber Gibson

    Dr Amber Gibson, Analyst, Datamonitor

  • Vaccine specific manufacturing issues
  • Production capacity across the EU and US
  • Case study analysis of manufacturing strategies for specific company types
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Vaccines for the Developing World
    Workshop

    Vaccines for the Developing World

    The Hatton, at etc. venues
    8th November 2002
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.